Unknown

Dataset Information

0

Hepatitis C therapy with interferon-? and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.

ABSTRACT: Combined treatment with interferon alpha (IFN-?) and ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown. Here, we show that treatment with IFN-?/RBV led to a moderate but significant and sustained decline of HIV-1 DNA in CD4 T cells from HIV-1/hepatitis C virus-coinfected patients receiving highly active antiretroviral therapy (n = 12). However, in vitro experiments failed to demonstrate an effect of pharmacological doses of IFN-? on HIV-1 reactivation. Together, these data suggest that treatment with IFN-?/RBV can moderately reduce the reservoir of HIV-1-infected CD4 T cells that persists despite suppressive antiretroviral therapy.

SUBMITTER: Sun H 

PROVIDER: S-EPMC3982848 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.

Sun Hong H   Buzon Maria J MJ   Shaw Amy A   Berg Randi Karteebahn RK   Yu Xu G XG   Ferrando-Martinez Sara S   Leal Manuel M   Ruiz-Mateos Ezequiel E   Lichterfeld Mathias M  

The Journal of infectious diseases 20131125 9

Combined treatment with interferon alpha (IFN-α) and ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown. Here, we show that treatment with IFN-α/RBV led to a moderate but significant and sustained decline of HIV-1 DNA in CD4 T cells from HIV-1/hepatitis C virus-coinfected patients receiving highly active antiretroviral therapy (n = 12). However,  ...[more]

Similar Datasets

Unknown Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.
| S-EPMC2924472 | biostudies-literature
Unknown IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
| S-EPMC4892378 | biostudies-literature
Unknown Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
| S-EPMC4760418 | biostudies-literature
Unknown Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
| S-EPMC4416933 | biostudies-literature
Unknown Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.
| S-EPMC3695611 | biostudies-literature
Unknown Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans.
| S-EPMC3922212 | biostudies-literature
Unknown Inteleukin-23 promotes interferon-? responsiveness in hepatitis C virus/HIV-coinfected patients.
| S-EPMC4118700 | biostudies-literature
Unknown Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
| S-EPMC2881334 | biostudies-literature
Unknown Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy.
| S-EPMC2982956 | biostudies-literature
Unknown Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients.
| S-EPMC4110185 | biostudies-literature